Compare Micron Technology, Inc. (MU) vs Novavax Inc (NVAX) Price & Performance

Micron Technology (MU) trades at $1,000.26, down 1.61% on the day, but remains in a bullish technical trend with strong analyst support. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Fundamentals show robust growth, with 2025 revenue at $37.38 billion and net income margin of 55.91%. Positive sentiment is driven by AI-driven memory demand and projected 2026 revenue of $90.3 billion.

Outlook is bullish given memory supply constraints and AI tailwinds, but risks include cyclical industry volatility and high valuation multiples. The consensus price target is $1,540 with 82.9% of analysts rating it a buy. Investors should weigh strong cash flow growth against potential margin pressures if demand softens.

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.